title: Sulfasalazine-induced angioimmunoblastic lymphadenopathy developing in a patient with juvenile chronic arthritis.
abstract: We describe a patient with juvenile chronic arthritis who developed reactive angioimmunoblastic lymphadenopathy, induced by sulfasalazine. Development of angioimmunoblastic lymphadenopathy although rare, is a very serious side effect of sulfasalazine treatment, and patients treated with this drug should be watched carefully.
authors.affiliation: GATA Romatoloji Bilim Dah, Etlik, Ankara, Turkey. isimsek1@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Pay
authors.forename: A
authors.initials: A
authors.lastname: Dinc
authors.forename: I
authors.initials: I
authors.lastname: Simsek
authors.forename: C
authors.initials: C
authors.lastname: Can
authors.forename: H
authors.initials: H
authors.lastname: Erdem
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D002738:Chloroquine / Q000633:toxicity; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects*
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D002738:Chloroquine; D008775:Methylprednisolone; D008727:Methotrexate